巴曲酶治疗进展性脑梗死的血液流变学及疗效观察  

The evaluation of efficacy and safety of batroxobin （ DF - 521 ） in treatment of progressive cerebral infarctions.

作　　者：周江 马艳 黄翔 唐骏 皮小蓉 

机构地区：[1]岳阳市人民医院神经内科,湖南岳阳414000

出　　处：《中国卫生产业》2007年第07X期26-27,共2页China Health Industry

摘　　要：目的 评价巴曲酶（DF-521）治疗进展性脑梗死的血液流变学变化及临床疗效、安全性观察。方法 采用随机分组，安慰剂对照方式分为试验组及对照组，两组均采用丹参注射液作为基础治疗，试验组采用DF-521注射液静点，对照组加安慰剂静点，均为隔日1次，共3次，同时对治疗组血液流变学进行动态观察。结果 DF-521能改善血液流变学的某些因素；对血小板数、出凝血时间、肝肾功能无不良影响。试验组疗效明显优于对照组。结论 DF-521治疗进展性脑梗死疗效肯定，而且安全性高，不良反应少，宜于早期应用。Objective To evaluate the efficacy and safety of batroxobin （ DF - 521 ） in the treatment of progressive cerebral infarctions. Methods A Randomized clinical trial including a test group and a control group was conducted. Patients in each group were treated with dan sheng （ Radix Salviate Miltiorshizec） injection as a basic treatment. Batroxobin was added to the test group, while the placebo was added to the control group every other day for totally 3 therapeutic days. Results Batroxobin （ DF - 521 ） can improve some hemorheological findings, and it has no adverse effects on figures of platelet count, bleeding and coagulating time and liver and kidney function. The clinical efficacy in the test group is significantly better than that of the control group, Conclusion Batroxobin （ DF - 521 ） is effective and safe in the treatment of patients with progressive cerebral infarctions. It should be used in early stage of the disease.

关 键 词：巴曲酶(DF-521) 进展性脑梗死 血液流变学 

分 类 号：R692.5[医药卫生—泌尿科学]